An analysis of clinical trials by the FDA statisticians showed the incidence of suicidal behaviour among the adults on venlafaxine to be not significantly different from fluoxetine or [[placebo]] [REF].
People stopping venlafaxine commonly experience [[SSRI discontinuation syndrome|discontinuation symptoms]] such as [[dysphoria]], [[headache]]s, [[nausea]], [[irritability]], [[emotional lability]], and [[Sleep disorder|sleep disturbance]] [REF].